Sara E. Lubitz, MD

Link:

https://www.researchgate.net/profile/Sara-Lubitz

Affiliations & Leadership

• Program Director of the Endocrinology, Diabetes and Metabolism Fellowship
• Medical Director of the Pituitary Center 

Education and Training

• Rutgers (formerly UMDNJ) New Jersey Medical School – MD degree 2003
  Newark, NJ
• Internal Medicine Residency, New York University School of Medicine - 2003-2006, New York, NY
• Chief Resident, Internal Medicine Residency, New York University School of Medicine - 2006-2007, New York, NY
• Fellowship Endocrinology Diabetes and Metabolism, New York University School of Medicine - 2007-2009, New York, NY

Select Honors and Awards

• Castle Connolly Top Doctor; Jersey Choice Top Doctors New Jersey Monthly; Best Doctors® in America; NJ Top Docs

Biography

Sara Lubitz, MD is an Associate Professor at Rutgers Robert Wood Johnson Medical School where she serves as Program Director for the Endocrinology Diabetes and Metabolism Fellowship. She earned her medical degree from Rutgers New Jersey Medical School (formerly UMDNJ) and completed Internal Medicine residency, chief residency, and Endocrinology fellowship at New York University.  Areas of clinical interest include pituitary, thyroid, adrenal disease and gender affirmation hormone therapy.  She serves as Medical Director of the Pituitary Center at Robert Wood Johnson University Hospital and runs clinical trials in Acromegaly, Cushing’s disease and hypoparathyroidism.  Dr. Lubitz is a leader in the field of medical education and has won numerous teaching awards.   On a local level, she is on the RBHS GME and serves on the RBHS Training and Development Subcommittee.   She is on the executive council of the Association for Program Directors in Endocrinology and Metabolism (APDEM) and has co-authored the Hypothalamic-Pituitary section of the APDEM fellowship curriculum.  Dr. Lubitz has also chaired the American Association of Endocrinology (AACAE) Fellows Education Subcommittee and is most recently vice-chair of the Education Oversight Committee coordinating all educational initiatives for AACE.  She is recognized clinically on a national level by Best Doctors® in America, Castel Connolly Top Doctor, and locally by NJ Top Docs and Jersey Choice Top Doctors.

Clinical Interests and Description

Sara Lubitz has a clinical interest in pituitary/adrenal disease, transgender care, and thyroid/parathyroid disease. She is considered an expert in acromegaly and is the medical director of the Pituitary Center at Robert Wood Johnson University Hospital.  She is a co-founder of the Adult Endocrinology Transgender Clinic which provides gender affirmation hormone therapy as part of the multidisciplinary RWJUH PROUD Gender Center of New Jersey.  She sees patients with a variety of thyroid and parathyroid conditions including hyperthyroidism, hypothyroidism, thyroid cancer and hypoparathyroidism.

Research Interests and Description

Sara Lubitz has a research interest in pituitary disease and hypoparathyroidism. She has been an investigator for eight clinical trials in acromegaly and two clinical trials in hypoparathyroidism and continues to investigate the burden of disease on patient quality of life.  As long-standing Program Director for the Endocrinology, Diabetes and Metabolism fellowship she is also interested in medical education research. 

Active research and clinical projects

• Expanded Access Program of Palopegteriparatide in Patients with Hypoparathyroidism Sponsor: Ascendis
• PARADIGHM: A Natural History Registry for Patients with Chronic Hypoparathyroidism Sponsor: Takeda
• Level 2 Comprehensive Care Center for Congenital Adrenal Hyperplasia

Publications

• Integrating Basic Science into Endocrine Clinical Electives. Bassin SR, Lubitz S. Med Sci Educ. 2023 Jun 30;33(4):835-839. doi: 10.1007/s40670-023-01824-w. PMID: 37546212
• A National Survey of United States-Based Endocrinologists Who Prescribe Gender-Affirming Hormone Therapy. Bisno DI, Lubitz S, Marshall I, Cohen DA. Endocr Pract. 2023 Jun;29(6):465-470. doi: 10.1016/j.eprac.2023.03.003. Epub 2023 Mar 9. PMID: 36906069
• Insulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trial. Singh B, Smith JA, Axelrod DM, Ameri P, Levitt H, Danoff A, Lesser M, de Angelis C, Illa-Bochaca I, Lubitz S, Huberman D, Darvishian F, Kleinberg DL. Breast Cancer Res. 2014 Nov 11;16(6):463. doi: 10.1186/s13058-014-0463-1. PMID: 25385439

Biography Link:

https://pubmed.ncbi.nlm.nih.gov/?term=sara+lubitz